INDUSTRY SPONSORED SYMPOSIA

by Volpara Solutions

19 July, 1830hrs

Venue Oasia Hotel Novena, Basement 1, Courtyard 1

1. Personalising Breast Screening using Artificial Intelligence

Mary Rickard

Consultant Radiologist , Sydney Breast Clinic

Dr Mary Rickard will speak on the earliest days of artificial intelligence in breast cancer screening, discuss its merits and possibilities, and then take us towards the future discussing some of the latest technologies.

2. Finding Signal in the Noise – Applying Artificial Intelligence and Machine Learning to Health

Gabe Rijpma

Senior Director – Health and Social Services, Microsoft Asia

Gabe Rijma will talk about the some of the latest ways that healthcare technology is evolving and innovating. He will discuss the latest concepts in artificial intelligence and explore how to find “Signal in the Noise”.

by Genomic Health

20 July, 1050hrs

Venue KKH Auditorium

TAILORx – Identifying the Right Patients for the Right Treatment

Dr Christy Russell, MD

Senior Director US Medical Affairs, Genomic Health Inc

Tumour genomic analysis has made a substantial contribution to the treatment of breast cancers. The traditional clinical parameters such as tumor size and grade are regarded as prognostic but not predictive. The Oncotype DX Breast Recurrence Score® test from Genomic Health Inc. in particular, has demonstrated its ability in guiding treatment decisions after breast surgery for hormone-receptor positive, HER2 negative breast cancer patients.
Dr Christy Russell will talk about the science of genomic testing in early breast cancers with the latest research data in the TAILORx trial.

by Novartis

20 July, 1310hrs

Venue KKH Auditorium

Evolving Combination Strategies in Management of HR+ve, HER2-ve Advanced Breast Cancer

Dr See Hui Ti

Medical Oncologist Consultant, Parkway Cancer Centre, Mount Elizabeth Hospital, Singapore.

The lunch symposium will focus on recent updates on HR+ HER2- advanced breast cancer treatment landscape, highlighting new data on the young breast cancer patients (MONALEESA-7 overall survival data). In addition, there will be extensive discussion on breast cancer specific mutations- the PIK3CA mutation: from its molecule conception, clinical trial results (SOLAR-1) and its role in breast cancer clinical landscape.

by Roche

20 July, 1525hrs

Venue KKH Auditorium

Breast Conservation after Neoadjuvant Therapy – the Hong Kong Experience

Prof Ava Kwong

Chief of Division of Breast Surgery at Queen Mary Hospital, Tung Wah Hospital and The University of Hong Kong-Shenzhen Hospital

Over the past decade, the treatment strategies in early breast cancer have evolved, resulting in improved patient outcomes. While both neo-adjuvant and adjuvant chemotherapy have been shown to have comparable survival benefit for the same standard regimens, neoadjuvant use of combination therapy has many advantages over adjuvant use. However, even with the curative-intent optimal surgery, patients with HER2-positive breast cancer carry high risk of recurrence. To dissect this topic further, Prof Ava Kwong will share her expertise with a focus on her experience in breast conservation after neoadjuvant therapy.